Bioinformatician
Aviv Regev (born 11 July 1971)[3] is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche.[4] She is a core member (on leave) at the Broad Institute of MIT and Harvard and professor (on leave) at the Department of Biology of the Massachusetts Institute of Technology.[5] Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project,[6] together with Sarah Teichmann.
Career and research
In 2020, Regev became the Head and Executive Vice President of Genentech Research and Early Development, based in South San Francisco, and a member of the extended Corporate Executive Committee of Roche.[9][10] Previously, she was a Core Institute Member (now on leave), Chair of the Faculty, Founding Director of the Klarman Cell Observatory and co-Director Cell Circuits Program at the Broad Institute of MIT and Harvard. She was also a professor in the Department of Biology at the Massachusetts Institute of Technology (now on leave), as well as an Investigator at the Howard Hughes Medical Institute. Regev's research[11] includes work on gene expression[12][13] (with Eran Segal and David Botstein), and the use of π-calculus to represent biochemical processes.[14][15][16] Regev's team has been a leading pioneer of single-cell genomics experimental and computational methods.[17] In 2014, she pitched the idea of the creation of Human Cell Atlas,[18] a project to describe all cell types in the human body. Regev founded the Human Cell Atlas together with Sarah Teichmann along with collaborators all over the world.
Single Cell Genomics
Regev's lab pioneered the development and application of many of the key experimental and computational advances for single cell and spatial genomics, especially single cell RNA-Seq (scRNA-seq).
Awards and honors
Regev is a fellow of the International Society of Computational Biology (ISCB) (2017),[19] a Helmholtz Fellow (2020),[20] and a fellow of the American Association for Cancer Research (AACR) (2021).[21] She is a member of the US National Academy of Sciences (NAS, elected 2019)[22] and of the US National Academy of Medicine (NAM, elected 2020).[23]
- 25th L'Oréal-UNESCO For Women in Science Awards (Laureate for North America), 2023[24]
- Elected to the American Academy of Arts and Sciences, 2022[25]
- Anderson Lecture, University of Virginia, 2022[26]
- Nakasone Award from the Human Frontiers Science Program (2022)[27]
- Honorary doctorate, ETH Zurich (2021)[28]
- Ernst Schering Prize (2021)[29]
- James Prize in Science and Technology Integration, National Academy of Sciences (2021)[30]
- Vanderbilt Prize (2021)[31]
- She was awarded the 25th Keio Medical Science Prize in 2020.[32][33]
- AACR-Irving Weinstein Foundation Distinguished Lecture (2021)[34]
- Lurie Prize from the Foundation for the NIH (FNIH) (2020)[35]
- Mendel Lecture, European Society of Human Genetics (2020)[36]
- Jonathan Kraft Prize from Massachusetts General Hospital (2020)[37]
- FASEB Excellence in Science Mid-Career Investigator Award (2019)[38]
- She was elected a member of the National Academy of Sciences (NAS) in 2019.[39]
- She also served on the Life Sciences jury for the Infosys Prize in 2018.
- Weatherall Lecture, University Oxford, UK (2018)[40]
- Harvey Lecture, Harvey Society, New York (2018)[41]
- McCormick Lecture, Stanford University (2018)[42]
- Paul Marks Prize for Cancer Research (2017).[43]
- ISCB Innovator Award in 2017.[2][44]
- Earl and Thressa Stadtman Scholar Award from the American Society of Biochemistry and Molecular Biology (ASBMB) (2014)[45]
- Burroughs Wellcome Fund Career Award.[46]
- In 2008, she was also awarded the NIH Director's Pioneer Award.[47][48]
- Regev was awarded the Overton Prize in 2008 for "outstanding accomplishment to a scientist in the early to mid stage of his or her career".[1]
.jpg)
